Organon Acquires Roivant's Dermavant for $1.2 Billion, Including VTAMA Cream

Sep 18, 2024, 11:36 AM

Organon has announced its acquisition of Dermavant, a subsidiary of Roivant Sciences ($ROIV), in a deal valued at $1.2 billion. The acquisition includes Dermavant's innovative dermatologic therapy, VTAMA (tapinarof) Cream, 1%. The deal involves an upfront payment of $175 million, with additional payments up to $1.2 billion contingent on sales milestones and approval in atopic dermatitis. This acquisition underscores Organon's commitment to expanding its portfolio in dermatology.